Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculo...
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
About this item
Full title
Author / Creator
Strydom, Natasha , Ernest, Jacqueline P. , Imperial, Marjorie , Solans, Belén P. , Wang, Qianwen , Tasneen, Rokeya , Tyagi, Sandeep , Soni, Heena , Garcia, Andrew , Bigelow, Kristina , Gengenbacher, Martin , Zimmerman, Matthew , Xie, Min , Sarathy, Jansy P. , Yang, Tian J. , Dartois, Véronique , Nuermberger, Eric L. and Savic, Radojka M.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL). We aim to optimize the dosing of TBI-223 within the BPaL regimen for enhanced therapeutic outcomes. TBI-223 is investigated in preclinical monotherapy, multidrug therapy, a...
Alternative Titles
Full title
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
Authors, Artists and Contributors
Author / Creator
Ernest, Jacqueline P.
Imperial, Marjorie
Solans, Belén P.
Wang, Qianwen
Tasneen, Rokeya
Tyagi, Sandeep
Soni, Heena
Garcia, Andrew
Bigelow, Kristina
Gengenbacher, Martin
Zimmerman, Matthew
Xie, Min
Sarathy, Jansy P.
Yang, Tian J.
Dartois, Véronique
Nuermberger, Eric L.
Savic, Radojka M.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9d1084b5f6bc4812a0fc0f521bbba61f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9d1084b5f6bc4812a0fc0f521bbba61f
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-024-50781-4
